Gynaecological cancers are among the leading causes of cancer-related death among women worldwide. Cancer cells undergo metabolic reprogramming to sustain the production of energy and macromolecules required for cell growth, division and survival. Emerging evidence has provided significant insights into the integral role of fatty acids on tumourigenesis, but the metabolic role of high endogenous oestrogen levels and increased gynaecological cancer risks, notably in obesity, is less understood. This is becoming a renewed research interest, given the recently established association between obesity and incidence of many gynaecological cancers, including breast, ovarian, cervical and endometrial cancers. This review article, hence, comprehensively discusses how FA metabolism is altered in these gynaecological cancers, highlighting the emerging role of oestradiol on the actions of key regulatory enzymes of lipid metabolism, either directly through its classical ER pathways, or indirectly via the IGIFR pathway. Given the dramatic rise in obesity and parallel increase in the prevalence of gynaecological cancers among premenopausal women, further clarifications of the complex mechanisms underpinning gynaecological cancers are needed to inform future prevention efforts. Hence, in our review, we also highlight opportunities where metabolic dependencies can be exploited as viable therapeutic targets for these hormone-responsive cancers.
Excessive deposit of epicardial adipose tissue (EAT) were recently shown to be positively correlated with cardiovascular disease (CVD). This study aims to investigate the thickness of EAT and its association with the components of metabolic syndrome among multi-ethnic Malaysians with and without acute coronary syndrome (ACS). A total of 213 patients were recruited, with the thickness of EAT were quantified non-invasively using standard two-dimensional echocardiography. EAT thickness among the Malaysian population was prompted by several demographic factors and medical comorbidities, particularly T2DM and dyslipidaemia. ACS patients have significantly thicker EAT compared to those without ACS (4.1 mm vs 3.7 mm, p = 0.035). Interestingly, among all the races, Chinese had the thickest EAT distribution (4.6 mm vs 3.8 mm), with age (p = 0.04 vs p < 0.001), and overall diastolic blood pressure (p = 0.028) was also found to be associated with EAT thickness. Further study is warranted to investigate its role as a cardiovascular risk marker among Malaysians with ACS.
Obesity is strongly linked with increased risk and poorer prognosis of endometrial cancer (EC). Cancer-associated fibroblasts (CAFs) are activated fibroblasts that form a large component of the tumor microenvironment and undergo metabolic reprogramming to provide critical metabolites for tumor growth. However, it is still unknown how obesity, characterized by a surplus of free fatty acids drives the modifications of CAFs lipid metabolism which may provide the mechanistic link between obesity and EC progression. The present study aims to evaluate the utility of Raman spectroscopy, an emerging nondestructive analytical tool to detect signature changes in lipid metabolites of CAFs from EC patients with varying body mass index. We established primary cultures of fibroblasts from human EC tissues, and CAFs of overweight/obese and nonobese women using antibody-conjugated magnetic beads isolation. These homogeneous fibroblast cultures expressed fibroblast markers, including α-smooth muscle actin and vimentin. Analysis was made in the Raman spectra region best associated with cancer progression biochemical changes in lipids (600–1800 cm –1 and 2800–3200 cm –1 ). Direct band analysis and ratiometric analysis were conducted to extract information from the Raman spectrum. Present results demonstrated minor shifts in the CH 2 symmetric stretch of lipids at 2879 cm –1 and CH 3 asymmetric stretching from protein at 2932 cm –1 in the overweight/obese CAFS compared to nonobese CAFs, indicating increased lipid content and a higher degree of lipid saturation. Principal component analysis showed that CAFs from overweight/obese and nonobese EC patients can be clearly distinguished indicating the capability of Raman spectroscopy to detect changes in biochemical components. Our results suggest Raman spectroscopy supported by chemometric analysis is a reliable technique for characterizing metabolic changes in clinical samples, providing an insight into obesity-driven alteration in CAFs, a critical stromal component during EC tumorigenesis.
Epicardial adipose tissue (EAT) is an emerging cardiometabolic risk factor in type 2 diabetes mellitus (T2DM). While SGLT-2 inhibitors (SGLT-2i) offer cardiovascular benefits, their specific effects on EAT and left ventricular (LV) remodeling and function in Asian populations remain understudied. This study investigated the relationship between SGLT-2i on cardiometabolic parameters, EAT thickness and LV function in Malaysian patients with T2DM and coronary artery disease (CAD). A total of 360 patients with T2DM and CAD were divided into non-SGLT-2i and SGLT-2i groups. Anthropometric, cardiometabolic, and echocardiographic measurements were analyzed at baseline and post-6 months for 302 patients who competed the study (n = 151 per group). Both groups showed improvements in glycemic control (fasting blood glucose − 1.7 vs. − 2.6 mmol/L; HbA1c − 0.3% vs. − 0.6%; all p < 0.001). Broader cardiometabolic benefits were observed predominantly among SGLT-2i group, including greater reductions in body mass index (– 0.7 vs. − 0.3 kg/m2) and serum lipid concentrations (all p < 0.001), a marked decrease in EAT thickness (–1 .5 mm vs. + 0.6 mm, p < 0.001), and concomitant improvements in left ventricular structure, with reductions in LV mass (– 20 vs. + 7.8 g) and increased LV ejection fraction (+ 4.6% vs. − 1.0%) (all p ≤ 0.01). Within the SGLT-2i group, EAT reduction was associated with lower body weight and BMI (p < 0.05) but was independent of glycemic changes. Reductions in body weight and BMI were associated with improvements in LV diameter and mass (p < 0.05) and although not directly mediated by changes in EAT. Beyond glycemic control, SGLT-2i was associated with reduced EAT thickness and improved LV remodeling and function in Malaysian T2DM patients with CAD. The reduction in EAT thickness specifically was associated with lower body weight and BMI. These findings provide Asian population–specific evidence with distinct cardiometabolic and adiposity traits.
Endometrial cancer (EC) is intricately linked to obesity, with metabolic reprogramming increasingly established to drive oncogenic transformation and influence treatment outcomes. Implementation of early detection strategy significantly reduces morbidity and mortality; however, screening strategies lack the required sensitivity, specificity, and accuracy to be successfully implemented in clinical practice. Current diagnostic approaches are also invasive, costly, and time-consuming, highlighting a gap in developing diagnostic and screening alternatives for EC among high-risk individuals, especially with sensitivity to capture cancer-specific changes. Raman Spectroscopy is an emerging tool in medical diagnostics. By exploiting the atomic vibrational absorption induced by the interaction of light with a biological sample, a unique spectral response namely a "metabolite fingerprint" can be generated. This nondestructive technique combined with multivariate statistical analysis can characterize metabolic discrimination between cancerous and healthy samples, demonstrating a promising role in cancer screening, diagnosis, and monitoring of treatment outcomes. This review aimed to collate available evidence on Raman's ability to capture metabolic abnormalities, particularly cancer-specific metabolites during malignant transformation and therapeutic resistance. Given that cellular metabolism is altered in EC, this review will provide insight into its potential applications for EC screening, diagnosis, and prospects, especially for monitoring treatment outcomes among high-risk patients.